Koen Vandyck

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2837444/publications.pdf Version: 2024-02-01



KOEN VANDVCK

#	Article	IF	CITATIONS
1	Capsid Assembly Modulators Have a Dual Mechanism of Action in Primary Human Hepatocytes Infected with Hepatitis B Virus. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	112
2	Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. Current Opinion in Virology, 2021, 49, 36-40.	5.4	100
3	Novel Potent Capsid Assembly Modulators Regulate Multiple Steps of the Hepatitis B Virus Life Cycle. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	83
4	Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	51
5	Synthesis and Evaluation of <i>N</i> -Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV). Journal of Medicinal Chemistry, 2018, 61, 6247-6260.	6.4	40
6	Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development. Antiviral Research, 2021, 187, 105020.	4.1	37
7	Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry. Antiviral Research, 2020, 182, 104924.	4.1	33
8	ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits inÂvivo efficacy in a Syrian Hamster model. Biochemical and Biophysical Research Communications, 2021, 555, 134-139.	2.1	30
9	Characterization of a dengue NS4B inhibitor originating from an HCV small molecule library. Antiviral Research, 2017, 147, 149-158.	4.1	17
10	Development of a cellular high-content, immunofluorescent HBV core assay to identify novel capsid assembly modulators that induce the formation of aberrant HBV core structures. Journal of Virological Methods, 2021, 293, 114150.	2.1	6